



ALL

IMAGES

VIDEOS

开启取词

11,600 Results

Any time ▾

## Assessing the impact of chemotherapy-induced peripheral ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297756>

Dec 09, 2011 - Special neurotoxicity supplements have been added to QOL measures, such as the FACT-taxane , the **Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)** , and the Chemotherapy Induced Peripheral **neuropathy (CHIP)** [5, 7]. However, these measures fail to evaluate the effects of neurotoxicity on daily ...

Cited by: 60

Author: C. M. L. Driessen, K. M. E. de Kleine-Bol...

Publish Year: 2012

## (PDF) A descriptive study of persistent oxaliplatin ...

[https://www.researchgate.net/publication/257755365\\_A\\_descriptive\\_study\\_of\\_persistent...](https://www.researchgate.net/publication/257755365_A_descriptive_study_of_persistent...)

Questionnaires were sent to patients who completed treatment with oxaliplatin for colorectal cancer at least 20 months prior to entering the study. Neuropathy questions were adapted from the FACT ...

## Neurotoxicity From Oxaliplatin Combined With Weekly Bolus ...

<https://ascopubs.org/doi/10.1200/JCO.2006.08.6652>

Sep 21, 2016 - Patients in the PRO substudy completed the validated **Functional Assessment of Cancer Therapy (FACT)/Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity** questionnaire before random assignment; at week 4 of the second treatment cycle; and at the 6-, 12-, and 18-month follow-up visits. 11-13 The questionnaire is published online 13 and ...

Cited by: 255

Author: Stephanie R. Land, Jacek A. Kopec, Ree...

Publish Year: 2007

## Measuring therapy-induced peripheral neuropathy ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592444>

Patients with multiple myeloma treated primarily with bortezomib and patients with colorectal cancer receiving oxaliplatin evaluated candidate items. Cognitive debriefing showed that all items were easy to understand, and this preliminary TNAS demonstrated reliability, validity, and sensitivity.

Cited by: 7

Author: Tito R Mendoza, Xin Shelley Wang, Loret...

Publish Year: 2015

## Emotional responses to persistent chemotherapy-induced ...

[www.apjon.org/article.asp?issn=2347-5625;year=2017;volume=4;issue=3;spage=233;epage=...](http://www.apjon.org/article.asp?issn=2347-5625;year=2017;volume=4;issue=3;spage=233;epage=...)

Emotional responses to persistent chemotherapy-induced peripheral neuropathy experienced by patients with colorectal cancer in Japan Kiyoko Kanda 1, Kaiko Fujiwara 1, Ayumi Kuwata 2,1

## Match Overview

1	Internet 33 words crawled on 27-Aug-2014 <a href="http://www.mascc.org">www.mascc.org</a>	1%
2	Internet 32 words crawled on 19-Jun-2011 <a href="http://www.supportiveoncology.net">www.supportiveoncology.net</a>	1%
3	Internet 21 words crawled on 06-Jun-2015 <a href="http://www.stfrancismedical.org">www.stfrancismedical.org</a>	1%
4	Crossref 16 words Patrick O. Monahan, Victoria L. Champion, Qianqian Zhao, Anna M. Miller, David Gershenson, Stephen D. Williams, D	<1%
5	Internet 12 words crawled on 25-Oct-2018 <a href="http://www.eviq.org.au">www.eviq.org.au</a>	<1%
6	Internet 11 words crawled on 04-Mar-2017 <a href="http://mdr.uni-muenster.de">mdr.uni-muenster.de</a>	<1%
7	Crossref 10 words David Cella. "Measuring the side effects of taxane therapy i n oncology", Cancer, 08/15/2003	<1%

**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 51643

**Manuscript Type:** ORIGINAL ARTICLE

### *Observational Study*

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity scale

Karen Kaiser, Madison Lyleroeher, Sara Shaunfield, Leilani Lacson, Maria Corona, Sheetal Kircher, Malin Nittve, David Cella

### **Abstract**

#### **BACKGROUND**





ALL

IMAGES

VIDEOS

关闭取词

11,600 Results

Any time ▾

## Assessing the impact of chemotherapy-induced peripheral ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297756>

Dec 09, 2011 · Special neurotoxicity supplements have been added to QOL measures, such as the FACT-taxane , the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) , and the Chemotherapy Induced Peripheral neuropathy (CHIP) [5, 7]. However, these measures fail to evaluate the effects of neurotoxicity on daily ...

Cited by: 60

Author: C. M. L. Driessen, K. M. E. de Kleine-Bol...

Publish Year: 2012

## (PDF) A descriptive study of persistent oxaliplatin ...

[https://www.researchgate.net/publication/257755365\\_A\\_descriptive\\_study\\_of\\_persistent...](https://www.researchgate.net/publication/257755365_A_descriptive_study_of_persistent...)

Questionnaires were sent to patients who completed treatment with oxaliplatin for colorectal cancer at least 20 months prior to entering the study. Neuropathy questions were adapted from the FACT ...

## Neurotoxicity From Oxaliplatin Combined With Weekly Bolus ...

<https://ascopubs.org/doi/10.1200/JCO.2006.08.6652>

Sep 21, 2016 · Patients in the PRO substudy completed the validated Functional Assessment of Cancer Therapy (FACT)/Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity questionnaire before random assignment; at week 4 of the second treatment cycle; and at the 6-, 12-, and 18-month follow-up visits. 11-13 The questionnaire is published online 13 and ...

Cited by: 255

Author: Stephanie R. Land, Jacek A. Kopec, Ree...

Publish Year: 2007

## Measuring therapy-induced peripheral neuropathy ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592444>

Patients with multiple myeloma treated primarily with bortezomib and patients with colorectal cancer receiving oxaliplatin evaluated candidate items. Cognitive debriefing showed that all items were easy to understand, and this preliminary TNAS demonstrated reliability, validity, and sensitivity.

Cited by: 7

Author: Tito R Mendoza, Xin Shelley Wang, Loret...

Publish Year: 2015

## Emotional responses to persistent chemotherapy-induced ...

[www.apjon.org/article.asp?issn=2347-5625;year=2017;volume=4;issue=3;spage=233;epage=...](http://www.apjon.org/article.asp?issn=2347-5625;year=2017;volume=4;issue=3;spage=233;epage=...)